2. Academic Validation
  3. Initial testing of JNJ-26854165 (Serdemetan) by the pediatric preclinical testing program

Initial testing of JNJ-26854165 (Serdemetan) by the pediatric preclinical testing program

  • Pediatr Blood Cancer. 2012 Aug;59(2):329-32. doi: 10.1002/pbc.23319.
Malcolm A Smith 1,  Richard Gorlick,  E Anders Kolb,  Richard Lock,  Hernan Carol,  John M Maris,  Stephen T Keir,  Christopher L Morton,  C Patrick Reynolds,  Min H Kang,  Janine Arts,  Tarig Bashir,  Michel Janicot,  Raushan T Kurmasheva,  Peter J Houghton
Affiliations

Affiliation

  • 1 Cancer Therapy Evaluation Program, NCI, Bethesda, Maryland, USA. Malcolm.Smith@nih.gov
PMID: 21922647 DOI: 10.1002/pbc.23319
Abstract

JNJ-26854165 was originally developed as an activator of p53 capable of inducing Apoptosis in Cancer cell lines. In vitro, JNJ-26854165 demonstrated cytotoxic activity. The ALL cell line panel had a significantly lower median IC(50) (0.85 µM) than the remaining cell lines. In vivo JNJ-26854165 induced significant differences in EFS distribution compared to control in 18 of 37 solid tumors and in 5 of 7 of the evaluable ALL xenografts. Objective responses were observed in 4 of 37 solid tumor xenografts, and 2 of 7 ALL xenografts achieved PR or CR. Responses were noted in xenografts with both mutant and wild-type p53.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z